Marker Therapeutics Inc. has released a corporate presentation detailing the advancements and strategic positioning of its MAR-T Cell Platform, a non-genetically engineered technology developed at Baylor College of Medicine. The presentation highlights the lead clinical product, MT-601, which targets six tumor-specific antigens and has shown promising results in a Phase 1 clinical trial with a 78% response rate in lymphoma patients. The MAR-T technology is designed for both blood and solid tumors, offering a favorable safety profile without the risk of immune-effector cell associated neurotoxicity syndrome (ICANS). Marker Therapeutics has multiple FDA-cleared INDs for MAR-T based clinical programs and has secured over $30 million in non-dilutive funding. You can access the full presentation through the link below.